Szabolcs Szelinger

Research Assistant Professor

Translational Genomics Research Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Summary and list of detected and reported alterations by alteration type (CNV, SNV/Indel) and assay (both assays, Central Lab (CL) or Assay H only, Pilot Lab only). For both detected and reported variants, positive percent agreement (PPA) with Pilot Lab and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Scatter plots of continuous copy number results obtained from Central Lab (CL) or assay H and Designated Lab (DL) assay. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is for variants detected by both assays but not reported by at least one assay, and orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Purpose: NCI selected a network of Clinical Laboratory Improvement Amendments–certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms. Experimental Design: Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed for single-nucleotide variant, insertion and deletion, and copy-number variant classes. Results: We observed high concordance in variant detection between CL and DL for single-nucleotide variants and insertions and deletions [average positive agreement (APA) > 95.4% for all pairwise comparisons] but lower concordance for variant reporting after analysis pipeline filtering. We observed much higher agreement between CL and assays using amplification as the target enrichment method (84.2% 82%) except between CL and two assays (APA = 76.9% and 71.4%) due to differences in estimation of copy numbers. Notably, for all variants, differences in variant interpretation also contributed to reporting discrepancies. Conclusions: This study indicates that different NGS tumor profiling tests currently in widespread clinical use achieve high concordance between assays in variant detection. For variant reporting, observed discrepancies are mainly introduced during the bioinformatic analysis.

Year:

2025

Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Summary of detected and reported CNV alterations by assay (both assays, Central Lab (CL) or assay H only, Designated Lab (DL) assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated. Cytogenetics results for all concordance study samples and gene amplification measurements using different techniques: NGS, ddPCR, microarray and FISH

Year:

2025

A, Scatter plot of continuous VAF results between Central Lab (CL) or assay H and Pilot Lab. B, Scatter plot of continuous CN results. The large plot focuses on copy numbers up to 50, while the small inset shows the full range of CNV. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is detected but not reported by Pilot Lab, while orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Each worksheet shows all variants reported by a given Designated Laboratory, including those that are outside of the overlap region between the Central Assay and the Designated Laboratory Assay

Year:

2025

Scatter plots of continuous CN results obtained by NGS Central Lab (CL) or assay H, or NGS assay U and non-NGS techniques: A) ddPCR, B) microarray, C) FISH (Raw values) and D) FISH (Ratio). The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line.

Year:

2025

Scatter plots of continuous VAF results between assay H or CL and Designated Lab (DL) for SNV/Indel. The solid line demonstrates a Deming regression line, while the dashed line demonstrates the identity line. Black points denote variants which were reported by both assays, light green is for variants detected by both assays but not reported by at least one assay, and orange points denote variants that were only detected by CL. Circle is for variants detected by both assays. Triangle is for a variant detected by both assays but reported only by DL. Diamond is for a variant reported only by CL.

Year:

2025

Summary of detected above the NCI-MATCH cut off (VAF ≥5% and 10% for SNV and Indel respectively) and reported SNV/Indel by assay (both assays, Central Lab (CL) or assay H only, DL assay only). For both detected and reported variants, positive percent agreement (PPA) with DL and then CL as reference along with average percent agreement (APA), which is a weighted average of each PPA, were calculated.

Year:

2025

Collaborators (12)

Wenjuan Zhang

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Noah Brown

Assistant Professor

University of Michigan Hospital

UNITED STATES
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Peining Li

Professor

Yale University School of Medicine

UNITED STATES
View details

Michelle Afkhami, MD

Chief and Professor, Division of Molecular Pathology and Therapy Biomarkers

City of Hope

UNITED STATES
View details

Mahesh Mansukhani

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

Liqiang Xi

Staff Scientist

National Institutes of Health

UNITED STATES
View details

RAVINDRA KOLHE

Augusta University

UNITED STATES
View details

Eric Konnick

Associate Professor

University of Washington

UNITED STATES
View details

Zenta Walther

Associate Professor

Yale University School of Medicine

UNITED STATES
View details